Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight Insights
The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight Insights
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.